Status:
UNKNOWN
Ph1 Lobeline Interaction Study - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Methamphetamine Dependence
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.
Eligibility Criteria
Inclusion
- Be between the ages of 18 and 45 years of age
- Be in general good health with a history of methamphetamine (MA) abuse (but not dependence)
- If female and of child bearing potential, agrees to use birth control
- Be able to understand and provide written informed consent
- Have a body mass index between 18 and 30
- Have reported use of (MA) during the past three months without experiencing adverse consequence plus a life time MA or amphetamine use history of at least four occasions of use
- Have a negative drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening and at the time of admission
Exclusion
- Please contact site for details
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00439504
Last Update
January 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Langley Porter Psychiatric Institute
San Francisco, California, United States, 94143